---
title: "EXOZYMES INC. 2Q 2026: Revenue $0 Net loss $(5.25M) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295837889.md"
description: "Exozymes Inc. reported $0 revenue and a net loss of $5.25M for the six months ended June 30, 2026, as R&D activities increased. The company completed equity financings in June to support operations but disclosed substantial doubt regarding its 12-month runway. Management is pursuing additional grants, licensing opportunities, and potential financings to sustain near-term operations."
datetime: "2026-08-13T19:51:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295837889.md)
  - [en](https://longbridge.com/en/news/295837889.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295837889.md)
generator: "portal-rs"
---

# EXOZYMES INC. 2Q 2026: Revenue $0 Net loss $(5.25M) — 10-Q Summary

EXOZYMES INC. reported results for the quarter and six-month period ended June 30, 2026, showing no revenue and a net loss of $5.25M for the six-month period as the company increased R&D activity and completed equity financings to support near-term operations.

**Financial Highlights**

-   Revenue was $0 for 2Q 2026 and for the six months ended June 30, 2026 (no operating income reported).
-   Net income (loss) was $(5,248,861) for the six months ended June 30, 2026, versus $(4,216,707) in the prior-year period (loss widened (24.5%) year over year).
-   Diluted earnings per share: Not reported in the filing and therefore omitted.

**Business Highlights**

-   Capital raise & liquidity: Completed public and registered direct offerings in June 2026, providing net proceeds to support near-term operations.
-   R&D expansion: Research and development activity increased materially, driven by new hires, higher laboratory expenditures, increased stock-based compensation and reduced grant funding.
-   Grant and partnership momentum: Secured an NIH BioClick grant and a $3M portion of an NSF CFIRE industrial partnership to support work on the company’s cell-free platform.
-   Operational scale-up: The company hired additional staff and invested in lab equipment while scaling back certain IT and investor relations initiatives to reallocate resources.
-   Going concern & funding plan: Management disclosed substantial doubt about the company’s 12-month runway and is pursuing additional grants, licensing opportunities and potential financings.

Original SEC Filing: EXOZYMES INC. \[ EXOZ \] - 10-Q - Aug. 13, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [EXOZ.US](https://longbridge.com/en/quote/EXOZ.US.md)

## Related News & Research

- [EXOZ: NCT program exceeded targets; $6M raised and $2M NIH grant secured for R&D and commercialization](https://longbridge.com/en/news/296532185.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [Corning sets Q3 2026 dividend at R$ 0.25 per unit](https://longbridge.com/en/news/296635714.md)
- [REG - UIL Limited UIL Finance Ltd - Purchase of 2026 ZDP Shares](https://longbridge.com/en/news/296518280.md)
- [Public Storage announces R$ 0.41 per unit dividend for Q3 2026](https://longbridge.com/en/news/296635332.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**